Join our session RxE2 CEO, Gerald Finken, will be taking part in a panel titled: “The Integration of Clinical Trials and Clinical Care: A Revolution in the Participant and Sponsor Experience or an Implementation Nightmare? Or Both?” When & Where Monday, October 23, 2023 | 7:00 AM – 9:00 AM ET | Location:308 AB West Meet…
For the second consecutive year we’ve made the list of best tech startups! The Tech Tribune staff has compiled a list of the best tech startups in North Dakota. Several factors were considered in their research, including but not limited to: Revenue potential Leadership team Brand/product traction Competitive landscape RxE2 is honored to have been…
Fargo, ND August 17 2023 – RxE2 announces the appointment of Doug Liberi as VP of Business Development and Sales. In his role as VP of business development, Mr. Liberi will be in charge of category creation and market expansion for RxE2, leading the company’s sales team strategically. “I am happy Doug has agreed to…
While RxE2 continues promoting the practice of pharmacy and community-based pharmacists in clinical trials in the United States, the European Association of Hospital Pharmacies (EAHP) is encouraging the involvement of hospital pharmacists in European clinical trials. RxE2 applauds the EAHP for taking a position on clinical trials and their recognition of the valuable contributions pharmacists…
Fargo, ND, June 15, 2023 – This is the third year in which RxE2, led by CEO and two-time USA Cycling Masters National Cycling Champion, Gerald Finken, pledges $27,500 the NorthStar Cycling Club. “For over ten years NorthStar Development Cycling has shared the thrill of competitive cycling with scores of school-aged kids. Gerald Finken has…
RxE2 is disrupting the clinical supply chain to improve quality and eliminate waste – Meet us at #GCSG2023! Current supply chain logistics provide ample opportunity for risk and waste. What if we eliminate that? Led by Gerald E. Finken, the inventor of On-Demand Packaging & Labeling, RxE2 is de-risking the process by eliminating unnecessary steps for truly patient centric…
Diversity Now, the first protocol to achieve diversity in clinical trials according to the FDA guidelines for Race and Ethnicity Diversity Plans This plan provides a pharmacist-centered approach for compliance with Section V Categories 4 and 5 of the US Food and Drug Administration’s industry guidance (hereinafter “FDA Guidance”) for developing the required Race and…
Diversity in Clinical Trials – Background The Federal Drug Administration (FDA) issued non-compulsory guidance on clinical trial diversity to encourage diverse populations in clinical trials and improve the applicability of clinical trial results. The guidance recommends diverse clinical trial populations to better understand the safety and effectiveness of medical products across race, ethnicity, and gender.…
The Diversity Issue in Clinical Trials – an overview Pharmaceutical industry discussions on Diversity, Equity, and Inclusion (DEI) all end in the same place—the need to build patient trust. However, there are few suggestions about how to build this trust and little recognition that it will take time. Additionally, trust is only the first step…
Our team will be in San Francisco during the J.P. Morgan Healthcare Conference and is ready to meet with investors and industry leaders. We will also be taking part in the First Analysis Healthcare Technology Conference – 2023. Reach out to Gerald Finken or to David Stark to schedule a meeting!